Based onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This drugclass are thebackbone ofHR+ diseasePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis treatmentmodality isalwayscombined withlumpectomysurgery1%This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Preferredfrequencyof GnRHagonistsThe onlysteroidalaromataseinhibitor in itsdrug classDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialBased onOncotype DX,a score of 35will receivethis treatmentPreferredregimen forHR+ diseasefor frail/elderlypatientsThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent cancauseendometrialcancer, but hasbone densityprotective effectI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agentshould beinitiated withneratinib for thefirst 8 weeksUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression Based onTAILORx, <50years receivechemoendocrinetherapy if theyhave thisOncotypeDx score This drugclass are thebackbone ofHR+ diseasePatients who donot achieve pCRin HER2+disease and haveresidual diseaseget this therapyThis CDK 4/6inhibitor is the onlyone in its drugclass also used inearly stage breastcancerThis treatmentmodality isalwayscombined withlumpectomysurgery1%This agent canbe added toLN+ HER2+disease givenwithtrastuzumabThis drug class iscontraindicatedcombined withtrastuzumab-avoid for 7 monthsafter lasttrastuzumab doseThis should bemonitoredroutinely every3-4 monthswhile receivingtrastuzumab Preferredfrequencyof GnRHagonistsThe onlysteroidalaromataseinhibitor in itsdrug classDuration of timepatients willtakeabemaciclib inearly stagediseaseThis agent iswell studied fortamoxifeninduced hotflashes inbreast cancerThis prodrug isgiven in TNBC forpatients who do notachieve pathologiccomplete responsebased on CREATE-X trialBased onOncotype DX,a score of 35will receivethis treatmentPreferredregimen forHR+ diseasefor frail/elderlypatientsThis subtype ofbreast cancerhas the lowestrelative 5-yearsurvival rate This agent cancauseendometrialcancer, but hasbone densityprotective effectI can give thisagent in highrisk BRCA1/2 mutationfor 1 yearThis agentshould beinitiated withneratinib for thefirst 8 weeksUsed asneoadjuvant andadjuvant therapyin high risk TNBCbased on theKEYNOTE 522trialPatients withHER2+ diseasecontinuetargetedtherapy for thisdurationThe ATLAS,AttOM, MA.17Rtrials evaluatedthis durationbenefit ofendocrine therapyThis agent is notused inpremenopausalwomen as endocrinetherapy unless theyalso receive ovariansuppression 

BC questions - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Based on TAILORx, <50 years receive chemoendocrine therapy if they have this OncotypeDx score
  2. This drug class are the backbone of HR+ disease
  3. Patients who do not achieve pCR in HER2+ disease and have residual disease get this therapy
  4. This CDK 4/6 inhibitor is the only one in its drug class also used in early stage breast cancer
  5. This treatment modality is always combined with lumpectomy surgery
  6. 1%
  7. This agent can be added to LN+ HER2+ disease given with trastuzumab
  8. This drug class is contraindicated combined with trastuzumab- avoid for 7 months after last trastuzumab dose
  9. This should be monitored routinely every 3-4 months while receiving trastuzumab
  10. Preferred frequency of GnRH agonists
  11. The only steroidal aromatase inhibitor in its drug class
  12. Duration of time patients will take abemaciclib in early stage disease
  13. This agent is well studied for tamoxifen induced hot flashes in breast cancer
  14. This prodrug is given in TNBC for patients who do not achieve pathologic complete response based on CREATE-X trial
  15. Based on Oncotype DX, a score of 35 will receive this treatment
  16. Preferred regimen for HR+ disease for frail/elderly patients
  17. This subtype of breast cancer has the lowest relative 5-year survival rate
  18. This agent can cause endometrial cancer, but has bone density protective effect
  19. I can give this agent in high risk BRCA 1/2 mutation for 1 year
  20. This agent should be initiated with neratinib for the first 8 weeks
  21. Used as neoadjuvant and adjuvant therapy in high risk TNBC based on the KEYNOTE 522 trial
  22. Patients with HER2+ disease continue targeted therapy for this duration
  23. The ATLAS, AttOM, MA.17R trials evaluated this duration benefit of endocrine therapy
  24. This agent is not used in premenopausal women as endocrine therapy unless they also receive ovarian suppression